Holen Sie sich die Stockscreener-App
2.20
4.76%
-0.11
Vorhandelsmarkt:
2.21
0.010
+0.45%
Schlusskurs vom Vortag:
$2.31
Offen:
$2.28
24-Stunden-Volumen:
3.32M
Relative Volume:
0.59
Marktkapitalisierung:
$860.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.80M
KGV:
-6.2857
EPS:
-0.35
Netto-Cashflow:
$-68.07M
1W Leistung:
+5.26%
1M Leistung:
+0.00%
6M Leistung:
-20.86%
1J Leistung:
-34.13%
1-Tages-Spanne:
$2.17
$2.31
1-Wochen-Bereich:
$2.0326
$2.43
52-Wochen-Spanne:
$1.54
$3.97
Nuvation Bio Inc Stock (NUVB) Company Profile
Firmenname
Nuvation Bio Inc
Sektor
Branche
Telefon
(415) 754-3517
Adresse
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Vergleichen Sie NUVB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
2.20 | 860.87M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-26 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-03-08 | Eingeleitet | BTIG Research | Buy |
| 2021-03-08 | Eingeleitet | Cowen | Outperform |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Nuvation Bio's 16% Surge: A Deep Dive Into the Unseen Drivers - AInvest
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy - Nasdaq
Nuvation Bio's 11% Spike: A Deep Dive into the Unseen Drivers - AInvest
Nuvation Bio’s 7% Surge: A Technical and Market Flow Deep-Dive - AInvest
Nuvation Bio’s SWOT analysis: IBTROZI approval boosts stock prospects By Investing.com - Investing.com South Africa
Nuvation Bio’s SWOT analysis: IBTROZI approval boosts stock prospects - Investing.com
Positive week for Nuvation Bio Inc. (NYSE:NUVB) institutional investors who lost 31% over the past year - simplywall.st
RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating - MSN
JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans - MSN
Nuvation Bio Inc.(NYSE: NUVB) added to Russell 2500 Growth Index - MarketScreener
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Nuvation Bio's Taletrectinib Emerges as a Niche Oncology Leader with NCCN Endorsement - AInvest
Nuvation Bio (NUVB) Gains NCCN Endorsement for Taletrectinib in - GuruFocus
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers - Yahoo Finance
Nuvation Bio jumps after insiders purchase shares worth over $1.1M - MSN
Insider Buying: Stacy Markel Acquires 10,000 Shares of Nuvation Bio Inc (NUVB) - GuruFocus
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price - GuruFocus
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price Target | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Target Price Revised Amid Commercial Shift | NUVB Stock News - GuruFocus
RBC Cuts Price Target on Nuvation Bio to $6 From $10, Keeps Outperform, Speculative Risk - MarketScreener
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - The Manila Times
Onco360 Has Been Selected as a National Specialty Pharmacy - GlobeNewswire
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects - Investing.com India
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects By Investing.com - Investing.com Nigeria
Nuvation Bio stock holds steady as FDA approves lung cancer drug - Investing.com India
Buy Rating for Nuvation Bio’s IBTROZI: FDA Approval and Competitive Edge in ROS1+ NSCLC Treatment - TipRanks
Nuvation Bio price target maintained at $6 by Citizens JMP - Investing.com South Africa
FDA Approves Nuvation Bio’s Ibtrozi for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer - PharmExec
'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals
U.S. FDA Approves Nuvation Bio’s Ibtrozi - Contract Pharma
Nuvation Scores First FDA Nod With Oral Lung Cancer Drug - BioSpace
Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtro - GuruFocus
FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer - PMLiVE
Nuvation Bio stock falls after FDA approves lung cancer drug By Investing.com - Investing.com Canada
FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC - The Pharma Letter
Nuvation Bio stock falls after FDA approves lung cancer drug - Investing.com
Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi - MSN
FDA clears Nuvation's first product Ibtrozi, for lung cancer - pharmaphorum
Nuvation Bio (NUVB) Gains FDA Approval for Lung Cancer Drug Ibtr - GuruFocus
Nuvation Bio (NUVB) Trading Halted Amidst Anticipated Announceme - GuruFocus
FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche - BioPharma Dive
Nuvation Bio’s IBTROZI Receives FDA Approval - TipRanks
Nuvation Set For First Launch With Ibtrozi In Lung Cancer - insights.citeline.com
Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer Drug IBTROZI | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wed - GuruFocus
Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wedbush | NUVB Stock News - GuruFocus
# FDA approves Nuvation Bio’s lung cancer drug taletrectinib By Investing.com - Investing.com South Africa
US FDA approves Nuvation Bio’s lung cancer therapy - WSAU
US FDA approves Nuvation Bio's rare lung cancer drug - Reuters
Finanzdaten der Nuvation Bio Inc-Aktie (NUVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvation Bio Inc-Aktie (NUVB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sauvage Philippe | Chief Financial Officer |
Jun 17 '25 |
Buy |
1.79 |
4,000 |
7,160 |
9,902 |
| Sauvage Philippe | Chief Financial Officer |
Jun 16 '25 |
Buy |
1.83 |
3,300 |
6,056 |
5,902 |
| Sjogren Colleen | Chief Commercial Officer |
Jun 16 '25 |
Buy |
1.81 |
50,000 |
90,350 |
81,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 16 '25 |
Buy |
1.79 |
50,000 |
89,740 |
50,000 |
| Hung David | PRESIDENT AND CEO |
Jun 16 '25 |
Buy |
1.79 |
500,000 |
893,500 |
59,281,054 |
| Liu Dongfang | CHIEF MEDICAL OFFICER |
May 02 '25 |
Option Exercise |
1.94 |
20,000 |
38,800 |
32,000 |
| Liu Dongfang | CHIEF MEDICAL OFFICER |
May 02 '25 |
Sale |
2.50 |
20,000 |
50,024 |
12,000 |
2.10%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):